See more : Selan Exploration Technology Limited (SELAN.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Silence Therapeutics plc (SLN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Silence Therapeutics plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tullow Oil plc (TUWOY) Income Statement Analysis – Financial Results
- Norte Grande S.A. (NORTEGRAN.SN) Income Statement Analysis – Financial Results
- JIANGXI BESTOO ENE (001376.SZ) Income Statement Analysis – Financial Results
- Rewardle Holdings Limited (RXH.AX) Income Statement Analysis – Financial Results
- Carnation Industries Limited (CARNATIN.BO) Income Statement Analysis – Financial Results
Silence Therapeutics plc (SLN)
About Silence Therapeutics plc
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.38M | 17.50M | 12.42M | 5.48M | 244.00K | 0.00 | 16.00K | 770.00K | 0.00 | 15.00K | 117.00K | 163.00K | 694.00K | 2.37M | 1.72M | 2.21M | 4.05M | 1.95M | 509.00K | 159.00K | 1.34M | 1.15M | 138.00K | 959.00K | 1.37M | 210.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 10.32M | 10.88M | 7.46M | 3.76M | 0.00 | 9.74M | 7.94M | 8.71M | 7.11M | 8.88M | 5.65M | 3.38M | 3.36M | 5.82M | 5.07M | 6.71M | 4.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 15.06M | 6.62M | 4.96M | 1.72M | 244.00K | -9.74M | -7.93M | -7.94M | -7.11M | -8.87M | -5.53M | -3.22M | -2.67M | -3.46M | -3.35M | -4.50M | -796.00K | 1.95M | 509.00K | 159.00K | 1.34M | 1.15M | 138.00K | 959.00K | 1.37M | 210.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 59.34% | 37.83% | 39.94% | 31.34% | 100.00% | 0.00% | -49,543.75% | -1,031.30% | 0.00% | -59,126.67% | -4,727.35% | -1,972.39% | -384.29% | -146.03% | -194.43% | -203.85% | -19.67% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 44.03M | 35.61M | 30.77M | 20.21M | 13.34M | 9.74M | 7.94M | 8.71M | 7.11M | 8.88M | 5.65M | 3.38M | 3.36M | 5.82M | 5.07M | 6.71M | 4.84M | 3.19M | 1.66M | 1.70M | 3.01M | 2.46M | 2.49M | 3.00M | 3.05M | 1.68M | 1.83M | 986.00K | 790.00K |
| General & Administrative | 20.64M | 19.61M | 20.01M | 13.98M | 9.64M | 10.83M | 6.46M | 3.97M | 2.66M | 3.26M | 3.54M | 2.61M | 2.65M | 5.13M | 3.19M | 3.29M | 4.99M | 3.03M | 2.75M | 1.83M | 1.01M | 700.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.64M | 19.61M | 20.01M | 13.98M | 9.64M | 10.83M | 6.46M | 3.97M | 2.66M | 3.26M | 3.54M | 2.61M | 2.65M | 5.13M | 3.19M | 3.29M | 4.99M | 3.03M | 2.75M | 1.83M | 1.01M | 700.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 3.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -269.00K | 7.00K | -112.00K | -20.00K | 72.00K | -154.00K | -21.00K | 56.00K | -1.00K | -216.00K | -287.00K | 673.00K | 693.00K | 503.00K | 429.00K | 329.00K | 258.00K | 143.00K |
| Operating Expenses | 64.66M | 55.21M | 50.77M | 37.56M | 22.98M | 20.57M | 14.41M | 12.68M | 9.77M | 12.14M | 9.19M | 5.99M | 2.65M | 5.13M | 4.18M | 3.29M | 4.84M | 6.21M | 4.40M | 3.53M | 4.02M | 3.16M | 3.17M | 3.69M | 3.55M | 2.11M | 2.16M | 1.24M | 933.00K |
| Cost & Expenses | 74.98M | 66.09M | 58.23M | 41.33M | 22.98M | 20.57M | 14.41M | 12.68M | 9.77M | 12.14M | 9.19M | 5.99M | 6.01M | 10.95M | 9.26M | 10.00M | 9.68M | 6.21M | 4.40M | 3.53M | 4.02M | 3.16M | 3.17M | 3.69M | 3.55M | 2.11M | 2.16M | 1.24M | 933.00K |
| Interest Income | 1.45M | 226.00K | 10.00K | 129.00K | 27.00K | 39.00K | 206.00K | 1.54M | 175.00K | 147.00K | 70.00K | 18.00K | 56.00K | 95.00K | 46.00K | 357.00K | 544.00K | 348.00K | 264.00K | 133.00K | 216.00K | 317.00K | 522.00K | 505.00K | 163.00K | 324.00K | 398.00K | 279.00K | 59.00K |
| Interest Expense | 34.00K | 47.00K | 8.00K | 323.00K | 163.00K | 0.00 | 15.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.00K | 63.00K | 0.00 | -31.00K | 0.00 | 20.00K | 1.00K | 71.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -398.00K | -279.00K | -59.00K |
| Depreciation & Amortization | 498.00K | 482.00K | 427.00K | 496.00K | 482.00K | 399.00K | 433.00K | 310.00K | 182.00K | 332.00K | 297.00K | 252.00K | 305.00K | 323.00K | 371.00K | 423.00K | 318.00K | 353.00K | 216.00K | 38.00K | 44.00K | 56.00K | 42.00K | 29.00K | 6.00K | 36.00K | 34.00K | 34.00K | 1.00K |
| EBITDA | -49.78M | -47.89M | -45.42M | -35.53M | -22.36M | -20.17M | -3.33M | -11.60M | -9.59M | -11.80M | -8.78M | -5.31M | -5.42M | -8.17M | -7.12M | -7.44M | -5.32M | -3.59M | -3.42M | -3.20M | -2.63M | -1.95M | -2.99M | -2.71M | -2.17M | -1.87M | -2.13M | -1.21M | -932.00K |
| EBITDA Ratio | -196.17% | -273.61% | -365.50% | -642.85% | -9,108.61% | 0.00% | -208,962.50% | -1,505.97% | 0.00% | -78,633.33% | -7,500.00% | -3,409.82% | -713.69% | -345.31% | -413.06% | -317.43% | -117.91% | -183.10% | -669.94% | -2,010.06% | -179.54% | -143.09% | -2,163.04% | -282.17% | -158.61% | -889.05% | 0.00% | 0.00% | 0.00% |
| Operating Income | -49.60M | -48.59M | -45.81M | -35.85M | -22.73M | -20.57M | -14.39M | -11.91M | -9.77M | -12.13M | -9.07M | -26.31M | -5.79M | -8.66M | -7.55M | -7.79M | -5.79M | -4.27M | -3.90M | -3.37M | -2.67M | -2.01M | -3.03M | -2.74M | -2.18M | -1.90M | -2.16M | -1.24M | -933.00K |
| Operating Income Ratio | -195.48% | -277.66% | -369.02% | -654.26% | -9,317.21% | 0.00% | -89,943.75% | -1,546.23% | 0.00% | -80,846.67% | -7,753.85% | -16,143.56% | -833.72% | -365.93% | -438.42% | -352.74% | -143.02% | -219.21% | -765.82% | -2,118.24% | -198.88% | -174.20% | -2,193.48% | -285.19% | -159.05% | -906.19% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -706.00K | 1.23M | -42.00K | -194.00K | -136.00K | 45.00K | 10.62M | 1.54M | 340.00K | 147.00K | 70.00K | -20.46M | 49.00K | -137.00K | 46.00K | 357.00K | 544.00K | 328.00K | 263.00K | 62.00K | 216.00K | 302.00K | 479.00K | 505.00K | 163.00K | 324.00K | 398.00K | 279.00K | 59.00K |
| Income Before Tax | -50.31M | -47.37M | -45.86M | -36.04M | -22.87M | -20.53M | -3.78M | -10.36M | -9.43M | -11.98M | -9.00M | -26.28M | -5.74M | -8.80M | -7.51M | -7.44M | -5.24M | -3.94M | -3.64M | -3.31M | -2.46M | -1.70M | -2.55M | -2.23M | -2.02M | -1.58M | -1.76M | -965.00K | -874.00K |
| Income Before Tax Ratio | -198.27% | -270.66% | -369.36% | -657.80% | -9,372.95% | 0.00% | -23,593.75% | -1,345.71% | 0.00% | -79,866.67% | -7,694.02% | -16,125.15% | -826.66% | -371.72% | -435.75% | -336.58% | -129.58% | -202.36% | -714.15% | -2,079.25% | -182.81% | -147.96% | -1,846.38% | -232.53% | -147.15% | -751.90% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -7.04M | -6.88M | -6.45M | -3.49M | -3.29M | -2.12M | -2.16M | -1.92M | -2.78M | -892.00K | -70.00K | -30.00K | -49.00K | 137.00K | -37.00K | -357.00K | -136.00K | -114.00K | -50.00K | -350.00K | -177.00K | -220.00K | -354.00K | -286.00K | 124.00K | -324.00K | -398.00K | -279.00K | -59.00K |
| Net Income | -43.27M | -40.49M | -39.41M | -32.55M | -19.58M | -18.41M | -1.62M | -8.44M | -6.65M | -11.09M | -9.00M | -26.28M | -5.74M | -8.80M | -7.47M | -7.44M | -5.11M | -3.83M | -3.59M | -2.96M | -2.28M | -1.48M | -2.19M | -1.94M | -2.14M | -1.58M | -1.76M | -965.00K | -874.00K |
| Net Income Ratio | -170.51% | -231.35% | -317.44% | -594.03% | -8,025.41% | 0.00% | -10,112.50% | -1,096.10% | 0.00% | -73,920.00% | -7,694.02% | -16,125.15% | -826.66% | -371.72% | -433.60% | -336.58% | -126.22% | -196.51% | -704.32% | -1,859.12% | -169.64% | -128.84% | -1,589.86% | -202.71% | -156.20% | -751.90% | 0.00% | 0.00% | 0.00% |
| EPS | -1.17 | -1.26 | -1.33 | -1.19 | -0.78 | -0.79 | -0.07 | -0.36 | -0.31 | -0.66 | -0.61 | -4.11 | -1.84 | -4.74 | -8.32 | -9.30 | -6.59 | -6.03 | -8.83 | -18.57 | -14.33 | -9.32 | -13.79 | -12.77 | -15.59 | -12.00 | -13.68 | -7.59 | -7.95 |
| EPS Diluted | -1.17 | -1.26 | -1.33 | -1.19 | -0.78 | -0.79 | -0.07 | -0.36 | -0.31 | -0.66 | -0.61 | -4.11 | -1.84 | -4.74 | -8.32 | -9.30 | -6.59 | -6.03 | -8.83 | -18.57 | -14.33 | -9.32 | -13.79 | -12.77 | -15.59 | -12.00 | -13.68 | -7.59 | -7.95 |
| Weighted Avg Shares Out | 37.09M | 32.19M | 29.65M | 27.26M | 25.04M | 23.44M | 23.31M | 23.27M | 21.34M | 16.81M | 14.64M | 6.39M | 3.11M | 1.86M | 897.60K | 799.24K | 775.31K | 634.26K | 405.84K | 159.15K | 159.07K | 159.07K | 159.07K | 152.23K | 137.25K | 131.57K | 128.69K | 127.20K | 109.93K |
| Weighted Avg Shares Out (Dil) | 37.09M | 32.19M | 29.65M | 27.26M | 25.04M | 23.44M | 23.31M | 23.27M | 21.34M | 16.81M | 14.64M | 6.39M | 3.11M | 1.86M | 897.60K | 799.24K | 775.31K | 634.26K | 405.84K | 159.15K | 159.07K | 159.07K | 159.07K | 152.23K | 137.25K | 131.57K | 128.69K | 127.20K | 109.93K |
Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today presented data from an analysis of its APOLLO phase...
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced preliminary results...
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced...
Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Giles...
Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced...
Silence Therapeutics to Participate in September Investment Conferences
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that company...
Silence Therapeutics to Participate in September Investment Conferences
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced...
Silence Therapeutics Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the...
Silence Therapeutics Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera
LONDON--(BUSINESS WIRE)---- $SLN--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that...
Silence Therapeutics Announces Pricing of Underwritten Offering
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc (Nasdaq: SLN) (“Silence”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced the pricing of an underwritten...
Source: https://incomestatements.info
Category: Stock Reports